Question-量化DCE的应用  什么情况下量化的DCE成像是有用的？有没有这样的例子？
======================================================================================

:date: 2015-11-01
:tags: Perfusion, DCE
:slug: utility-of-dce
:authors: Chunshan
:summary: 量化DCE的应用

原文链接:\ `When might quantitative DCE imaging be useful? Can you give some examples? <http://www.mri-q.com/utility-of-dce.html>`_

**概要** 
 .. figure:: http://www.mri-q.com/uploads/3/2/7/4/3274160/3776793_orig.png
    :alt: summary
    :align: center
    :width: 700

坦率的说，以目前DCE的发展水平，我对量化DCE广泛向临床中推广没有多少热情。仔细查看现有的文献，读者会发现测量参数的值在不同的研究机构中有显著地不同。如果比较不同的肿瘤（如淋巴瘤和胶质母细胞瘤），我注意到测量参数如Ktrans和ve统计上有显著差异，但是组间的重叠使得这些差异没有实践的价值。至今为止我们研究过的大多数脑肿瘤病例中，量化DCE只是与观察造影剂摄取的时间-信号强度曲线相比提高了诊断概率，与常规DSC或者弥散加权成像相比丰富了测量参数。如果你愿意相信并且想知道为什么一些人认为量化DCE成像有一个光明的未来，请继续往下读。

DCE成像的病理基础在于侵略性更强，恶性程度更高的肿瘤有更多的新血管生成（这一基础概念并非无懈可击）。为了给肿瘤迅速增殖的细胞提供营养物质，血流量和血容量通常会增加，组织中血管和血浆（vp）所占的比例也会增加。肿瘤血管表面积增加，而且有固有的泄露，因此它们的渗透性-表面积乘积增加，我们预计肿瘤的Ktrans也会变高。此外，恶性肿瘤往往有坏死区域，导致与良性肿瘤相比细胞外空间比例（ve）增大。

一个驱动肿瘤学家推动量化DCE成像的基本动机是DCE能够预测并监控肿瘤反应。一些新的化疗药物如bevacizumab和cediranib是针对血管内皮生长因子（VEGF），这些药物不直接对肿瘤细胞产生细胞毒性，因此不会导致肿瘤立即萎缩。然而，通过降低血管通透性影响Ktrans和vp，是一种可用于评估治疗效果的潜在量化方法。类似的原因，DCE参数也有望区分进展性肿瘤和假性进展肿瘤，区分肿瘤复发与肿瘤放射性坏死。我们的两个病例展示了DCE成像在脑肿瘤中的应用，如下图。

+---------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+
| .. figure:: http://www.mri-q.com/uploads/3/2/7/4/3274160/5325566_orig.jpg | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/82900_orig.jpg   | .. figure:: http://www.mri-q.com/uploads/3/2/7/4/3274160/5344914_orig.jpg  | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/3705154_orig.jpg | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/775851_orig.jpg  |
|    :alt: enhancement                                                      |    :alt: Ktrans                                                            |    :alt: ve                                                                |    :alt: vp                                                                |    :alt: follow-up                                                         |
|    :width: 200                                                            |    :width: 200                                                             |    :width: 200                                                             |    :width: 200                                                             |    :width: 200                                                             |
|                                                                           |                                                                            |                                                                            |                                                                            |                                                                            |
|    ↑ enhancement                                                          |    ↑ K\ :sup:`trans`                                                       |    ↑ v\ :sub:`e`                                                           |    ↑ v\ :sub:`p`                                                           |    10 months later                                                         |
+---------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+----------------------------------------------------------------------------+

上图：DCE预测复发性胶质瘤（阳性）。对比度显著增强，Ktrans，ve，vp显著升高。10个月后的随访显示肿瘤处于进展中

下图：在治疗脑胶质瘤中不能提供明确诊断结果的DCE评估。对比度显著增强，Ktrans和ve显著升高，vp稍微升高。能够确定这是肿瘤么？随访3年后仅表现为治疗相关变化，没有肿瘤进展或复发。

+-------------------------------------------------------------------------------+----------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| .. figure:: http://www.mri-q.com/uploads/3/2/7/4/3274160/9187206_orig.jpg?109 | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/7118231_orig.jpg?107   | .. figure:: http://www.mri-q.com/uploads/3/2/7/4/3274160/6752035_orig.jpg  | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/5385405_orig.jpg?103 | .. figure::  http://www.mri-q.com/uploads/3/2/7/4/3274160/2530223_orig.jpg |
|    :alt: enhancement                                                          |    :alt: Ktrans                                                                  |    :alt: ve                                                                |    :alt: vp                                                                    |    :alt: follow-up                                                         |
|    :width: 200                                                                |    :width: 200                                                                   |    :width: 200                                                             |    :width: 200                                                                 |    :width: 200                                                             |
|                                                                               |                                                                                  |                                                                            |                                                                                |                                                                            |
|    ↑ enhancement                                                              |    ↑ K\ :sup:`trans`                                                             |    ↑ v\ :sub:`e`                                                           |    slight ↑ v\ :sub:`p`                                                        |    3 year followup                                                         |
+-------------------------------------------------------------------------------+----------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------------------+----------------------------------------------------------------------------+

**参考材料**
    * Choi HS, KIm AH, Ahn SS, et al. `Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI <http://www.mri-q.com/uploads/3/2/7/4/3274160/choi_kjr-14-487.pdf>`_. Korean J Radiol 2013; 14:487-92. (sounds great, but remember that many of the low-grade gliomas enhance weakly, if at all, so DCE parameters will reflect this.)
    * Chikui T, Obara M, Simonetti AW, et al. `The principal (sp) of dynamic contrast enhanced MRI, the method of pharmacokinetic analysis, and its application in the head and neck region <http://www.mri-q.com/uploads/3/2/7/4/3274160/dental_480659.pdf>`_. Int J Dentistry 2012; doi:10.1155/2012/480659       
    * Fatterpekar GM, Galheigo D, Naryana A, et al. `Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum — use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI <http://www.mri-q.com/uploads/3/2/7/4/3274160/ajr2e112e7417.pdf>`_. Am J Roentgenol 2012; 198:19-26. (acutally about DSC, not DCE, but gives an excellent description of the pathology of treatment-related changes in brain tumors).
    * Kickingereder P, Sahm F, Wiestler B, et al. `Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation <http://www.mri-q.com/uploads/3/2/7/4/3274160/ajnr.a3915.full.pdf>`_. AJNR Am J Neuroradiol 2014; 35:1503-1508. (some statistical differences in DCE parameters noted, but significant overlap between the two diseases in my opinion makes the technique worthless.) 
    * Zhang N, Zhang L, Qui B, et al. `Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas <http://www.mri-q.com/uploads/3/2/7/4/3274160/zhangnihms365626.pdf>`_. J Magn Reson imaging 2012; 36:355-363.

**相关问题**
	* `How are quantitative DCE parameters extracted from the signal data? <http://www.mri-q.com/dce-tissue-parmeters.html>`_ 